伊托必利、铝碳酸镁及蒙脱石散联合治疗胆汁反流性胃炎的有效性及安全性分析

Analysis on the Effectiveness and Safety of Itopride,Hydrotalcite and Montmorillonite Powder in the Treatment of Bile Reflux Gastritis

目的探讨采用伊托必利、铝碳酸镁及蒙脱石散联合治疗胆汁反流性胃炎的有效性及安全性。方法将我院2020年1月至2020年12月收治的80例胆汁反流性胃炎患者随机分为治疗组与常规组,各40例。治疗组采用伊托必利、铝碳酸镁联合蒙脱石散治疗,常规组采用伊托必利联合铝碳酸镁治疗。比较两组的治疗效果、不良反应情况及治疗前后的血清IL-8、TNF-α水平。结果治疗组的治疗总有效率为95.00%,明显高于常规组的72.50%(P<0.05)。治疗组的不良反应发生率为7.50%,与常规组的5.00%比较差异无统计学意义(P>0.05)。治疗后,治疗组的IL-8、TNF-α水平均明显低于常规组(P<0.05)。结论伊托必利、铝碳酸镁及蒙脱石散联合治疗胆汁反流性胃炎患者疗效显著,可降低血清IL-8、TNF-α水平,且不会增加不良反应。

Objective To explore the effectiveness and safety of itopride,hydrotalcite and montmorillonite powder in the treatment of bile reflux gastritis.Methods 80 patients with bile reflux gastritis in our hospital from January 2020 to December 2020 were randomly divided into treatment group and routine group,with 40 cases in each group.The treatment group was treated with itopride,hydrotalcite and montmorillonite powder,and the routine group was treated with itopride and hydrotalcite.The treatment effect,adverse reactions,and the serum IL-8 and TNF-αlevels before and after treatment were compared between two groups.Results The total effective rate of treatment in the treatment group was 95.00%,significantly higher than 72.50%in the routine group(P<0.05).The incidence of adverse reactions in the treatment group was 7.50%,which had no statistical difference with 5.00%in the routine group(P>0.05).After treatment,the IL-8 and TNF-αlevels of the treatment group were significantly lower than those of the routine group(P<0.05).Conclusions Itopride,hydrotalcite and montmorillonite powder in the treatment of patients with bile reflux gastritis has significant efficacy,which can reduce the serum IL-8 and TNF-α levels,and do not increase the adverse reactions.